JP2005538692A - Ｋｃｎｊ９の異常発現に関連する癌における新規組成物および方法 - Google Patents

Ｋｃｎｊ９の異常発現に関連する癌における新規組成物および方法 Download PDF

Info

Publication number
JP2005538692A
JP2005538692A JP2003578392A JP2003578392A JP2005538692A JP 2005538692 A JP2005538692 A JP 2005538692A JP 2003578392 A JP2003578392 A JP 2003578392A JP 2003578392 A JP2003578392 A JP 2003578392A JP 2005538692 A JP2005538692 A JP 2005538692A
Authority
JP
Japan
Prior art keywords
protein
nucleic acid
gene
expression
cap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003578392A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538692A5 (enExample
Inventor
デイビッド ダブリュー． モーリス，
Original Assignee
サイグレス ディスカバリー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイグレス ディスカバリー， インコーポレイテッド filed Critical サイグレス ディスカバリー， インコーポレイテッド
Publication of JP2005538692A publication Critical patent/JP2005538692A/ja
Publication of JP2005538692A5 publication Critical patent/JP2005538692A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2003578392A 2002-03-20 2003-03-12 Ｋｃｎｊ９の異常発現に関連する癌における新規組成物および方法 Withdrawn JP2005538692A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/105,871 US7700274B2 (en) 2000-12-22 2002-03-20 Compositions and methods in cancer associated with altered expression of KCNJ9
PCT/US2003/007469 WO2003080639A1 (en) 2002-03-20 2003-03-12 Novel compositions and methods in cancer associated with altered expression of kcnj9

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009133821A Division JP2009232852A (ja) 2002-03-20 2009-06-03 Ｋｃｎｊ９の異常発現に関連する癌における新規組成物および方法

Publications (2)

Publication Number Publication Date
JP2005538692A true JP2005538692A (ja) 2005-12-22
JP2005538692A5 JP2005538692A5 (enExample) 2006-04-20

Family

ID=28452450

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003578392A Withdrawn JP2005538692A (ja) 2002-03-20 2003-03-12 Ｋｃｎｊ９の異常発現に関連する癌における新規組成物および方法
JP2009133821A Pending JP2009232852A (ja) 2002-03-20 2009-06-03 Ｋｃｎｊ９の異常発現に関連する癌における新規組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009133821A Pending JP2009232852A (ja) 2002-03-20 2009-06-03 Ｋｃｎｊ９の異常発現に関連する癌における新規組成物および方法

Country Status (6)

Country Link
US (2) US7700274B2 (enExample)
EP (1) EP1490388A4 (enExample)
JP (2) JP2005538692A (enExample)
AU (2) AU2003225750C1 (enExample)
CA (1) CA2479727A1 (enExample)
WO (1) WO2003080639A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054863A2 (en) * 2003-11-22 2005-06-16 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled inwardly rectifying potassium channel (girk 3)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079434A2 (en) * 2001-03-29 2002-10-10 Deltagen, Inc. Transgenic mice containing kir3.3 potassium channel gene disruptions
WO2003008583A2 (en) * 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5430136A (en) * 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5235033A (en) * 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5124246A (en) * 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5359100A (en) * 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5216141A (en) * 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
CA2049028A1 (en) 1989-03-07 1990-09-08 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5014802A (en) * 1990-06-04 1991-05-14 General Motors Corporation Rear steer controller
US5602240A (en) * 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5386023A (en) * 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5644048A (en) * 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
WO1993022443A1 (en) 1992-04-24 1993-11-11 Sri International In vivo homologous sequence targeting in eukaryotic cells
US5681697A (en) * 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
US5637684A (en) * 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5597909A (en) * 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5580731A (en) * 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5681702A (en) * 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US5759776A (en) * 1995-06-05 1998-06-02 California Pacific Medical Center Targets for breast cancer diagnosis and treatment
EP1295952A3 (en) 1996-01-23 2003-07-09 The Board of Trustees of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US5776683A (en) * 1996-07-11 1998-07-07 California Pacific Medical Center Methods for identifying genes amplified in cancer cells
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6074825A (en) * 1997-07-31 2000-06-13 Maine Medical Center Stable encapsulated reference nucleic acid and method of making
US6153441A (en) * 1998-02-17 2000-11-28 Smithkline Beecham Corporation Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof
US6417208B1 (en) * 1999-02-05 2002-07-09 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C
EP1358349A2 (en) 2000-06-05 2003-11-05 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
CA2416292A1 (en) 2000-06-29 2002-01-10 Deltagen, Inc. Transgenic mice containing targeted gene disruptions
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2002022660A2 (en) 2000-09-11 2002-03-21 Hyseq, Inc. Novel nucleic acids and polypeptides
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US20030216558A1 (en) 2000-12-22 2003-11-20 Morris David W. Novel compositions and methods for cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008583A2 (en) * 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
WO2002079434A2 (en) * 2001-03-29 2002-10-10 Deltagen, Inc. Transgenic mice containing kir3.3 potassium channel gene disruptions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6008062015, ＦＥＢＳ Ｌｅｔｔ．， ３５３ （１９９４） ｐ．３７−４２ *
JPN6008062023, Ｍｏｌ Ｇｅｎｅｔ Ｍｅｔａｂ．， ７３［１］ （２００１） ｐ．９７−１０３ *
JPN7008008701, Ｃｅｌｌ Ｓｉｇｎａｌｓ．， １１［１２］ （１９９９） ｐ．８７１−８８３ *

Also Published As

Publication number Publication date
AU2003225750B2 (en) 2010-04-22
EP1490388A1 (en) 2004-12-29
US20060121454A1 (en) 2006-06-08
CA2479727A1 (en) 2003-10-02
US7700274B2 (en) 2010-04-20
WO2003080639A1 (en) 2003-10-02
JP2009232852A (ja) 2009-10-15
US20100317003A1 (en) 2010-12-16
EP1490388A4 (en) 2007-10-24
AU2003225750C1 (en) 2010-09-02
AU2003225750A1 (en) 2003-10-08
AU2010202867A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
JP2006507794A (ja) 癌のための新規の組成物および方法
US20020042067A1 (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
JP2009195249A (ja) 癌のための新規の組成物および方法
JP2004510951A (ja) 結腸直腸癌を診断する新規の方法、組成物、結腸直腸癌調節のためのスクリーニング法
JP2005512558A (ja) 癌のための新規の組成物および方法
JP2009195241A (ja) 癌のための新規の組成物および方法
JP2009225807A (ja) Ｐｒｌｒの変化した発現に関連する癌における新規組成物および方法
US6455668B1 (en) Methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US20020068036A1 (en) Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators
WO2003035837A2 (en) Novel compositions and methods for cancer
JP2009195243A (ja) Ｔｂｘ２１の変更された発現に関連する癌における新規組成物および方法
JP2009195244A (ja) Ｍｃｍ３ａｐの変更された発現に関連する癌における新規組成物および方法
US20030022255A1 (en) Novel compositions and methods for breast cancer
JP2009232852A (ja) Ｋｃｎｊ９の異常発現に関連する癌における新規組成物および方法
US20030198951A1 (en) Novel methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
JP2009195242A (ja) Ｐｒｄｍ１１の変更された発現に関連する癌における新規組成物および方法
JP2005506514A (ja) 結腸直腸ガンおよび／または乳ガンの診断方法、結腸直腸ガンおよび／または乳ガンのモジュレータの組成物およびスクリーニング法
AU2003230669B2 (en) Novel compositions and methods in cancer associated with altered expression of TBX21
JP2004537710A (ja) 乳癌の診断及び治療の新規方法、組成物及び乳癌調節剤用の選別方法
WO2002021134A2 (en) Methods of diagnosing breast cancer and screening for modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090402

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100115

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100127

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100430

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120110